NKTX Research | Milton Maxwell

NKTX

Nkarta, Inc.

1.8200

-0.0200-1.09%

Dec 16, 4:00:00 PM EST

Upcoming Earnings

Report date

-/-

Earnings Call Transcripts

This Quarter (Q1 '26)

No earnings call transcript available yet

Last Quarter (Q4 '25)

No earnings call transcript available

Key Stats

Market Cap

129.27M

P/E (TTM)

Basic EPS (TTM)

-1.38

Dividend Yield

Recent Filings

10-Q

Q3 FY2025 results

11/10/25Nov 10, 2025

Nkarta narrowed its Q3 FY2025 operating loss to $27.3M from $33.8M y/y, as R&D expenses dropped 20% to $20.2M on lower personnel costs post-March workforce cut, while G&A fell to $7.1M despite a $0.8M right-of-use asset impairment from stock price decline. Net loss improved to $21.7M ($0.29/share) from $28.3M ($0.39/share), aided by $1.7M employee retention credit; YTD net loss narrowed to $76.7M from $82.9M. Cash and equivalents plus investments stood at $316.5M, funding operations at least 12 months. Operating cash burn slowed to $67.1M YTD (derived). No debt. Workforce cut sharpened focus. Clinical trial enrollment lags.

8-K

Q3 loss narrows, trials advance

11/10/25Nov 10, 2025

Nkarta reported Q3 2025 net loss of $21.7M, down from $28.3M last year, with R&D expenses dropping to $20.2M. NKX019 trials advanced: enrollment started in second dose-escalation cohort after iDSMB clearance and FDA-cleared lymphodepletion tweaks yielding deep B-cell depletion. Cash hit $316.5M. Funds into 2029. Trials humming.

8-K

Q2 loss narrows, cash to 2029

8/12/25Aug 12, 2025

Nkarta reported Q2 net loss of $23.0 million, down from $25.0 million last year, with R&D expenses at $20.8 million. Cash stood at $334.0 million on June 30, funding operations into 2029. NKX019 trials in autoimmune diseases enroll steadily; preliminary data due H2 2025. New CMO bolsters expertise.

10-Q

Q2 FY2025 results

8/12/25Aug 12, 2025

Nkarta trimmed operating expenses 11% y/y to $27.2M in Q2 FY2025 ended June 30, 2025, narrowing net loss to $23.0M ($0.31/share) from $25.0M ($0.34/share) a year earlier, thanks to lower R&D ($20.8M, down 10%) and G&A ($6.4M, down 15%) amid a March workforce cut of 34%. Cash burn eased to $48.4M YTD (derived), leaving $334M in cash equivalents and investments at quarter-end, with no debt. EPS aligns with 74M diluted shares. R&D focused on NKX019 Phase 1 trials in autoimmune diseases like lupus nephritis. Clinical trial delays from competition pose risks.

8-K

CMO shakeup for autoimmune pivot

6/6/25Jun 6, 2025

Nkarta's CMO David Shook resigned June 6, 2025, to chase oncology gigs, shifting from the company's new autoimmune push. Shawn Rose, MD PhD, steps in June 23 with deep immunology chops, having advanced drugs like Sotyktu. Shook consults through July 11. Leadership reset aligns expertise.

About

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

CEO

Mr. Paul J. Hastings

IPO

7/10/2020

Website

https://www.nkartatx.com

Employees

105

Sector

Healthcare

Industry

Biotechnology